Ya-Ting Huang, RN, NP, PhD, Li-Yu Chen, MS, Chih-Yi Wu, BD, Ya-Yao Huang, PhD, Yuh-Feng Wang, MD, PhD
Posted by the 2022 Annual Conference of SNM, Taiwan
Introduction
The incidence of prostate cancer is fourth place in the world, but the diagnostic tools for early detected prostatic cancer have limitations due to poor diagnostic performance. Multiparametric magnetic resonance imaging (mpMRI) has been promoted as an auxiliary diagnostic tool before prostate biopsy. Currently, prostate-specific membrane antigen (PSMA) such as 68Ga-PSMA-11 combined with positron emission tomography/computed tomography (PET/CT) are another acquaintance tool for detecting prostate cancer staging. The current meta-analysis noted a consistent detection performance between 68Ga-PSMA-11 PET and mpMRI for localized prostatic tumors and T-staging.